Standard Biotools (LAB) Cash from Investing Activities (QoQ) (2010 - 2026)
Standard Biotools (LAB) Cash from Investing Activities (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.02 Bn | 179.73 Bn | 6.27 Bn |
| 2 | Stryker | 132.13 Bn | 129.26 Bn | 3.81 Bn |
| 3 | Medtronic | 111.43 Bn | 102.21 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.97 Bn | 67.52 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.31 Bn | 44.64 Bn | 1.29 Bn |
| 6 | Dexcom | 28.91 Bn | 27.79 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.86 Bn | 26.58 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 28.12 Bn | 27.54 Bn | - |
| 9 | Koninklijke Philips | 24.33 Bn | 21.29 Bn | 2.01 Bn |
| 10 | Standard Biotools | 302.22 Mn | -152.96 Mn | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,476.74% |
| Dec 31, 2025 | -20.34% |
| Sep 30, 2025 | -124.29% |
| Jun 30, 2025 | 88.07% |
| Mar 31, 2025 | -43.15% |
| Dec 31, 2024 | 183.30% |
| Sep 30, 2024 | -161.45% |
| Jun 30, 2024 | -84.20% |
| Mar 31, 2024 | 2,524.91% |
| Dec 31, 2023 | 73.73% |
| Sep 30, 2023 | -224.42% |
| Jun 30, 2023 | -7.02% |
| Mar 31, 2023 | 7.23% |
| Dec 31, 2022 | 274.86% |
| Sep 30, 2022 | 107.77% |
| Jun 30, 2022 | -15,826.27% |
| Sep 30, 2021 | -18.76% |
| Jun 30, 2021 | -84.75% |
| Mar 31, 2021 | -498.91% |
| Dec 31, 2020 | -106.22% |